Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial
Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial
NEW YORK, NY / ACCESSWIRE / May 1, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today announced the completion of enrollment in the single dose portion of its Phase 1 trial involving PT00114, its synthetic stress-regulating peptide, for treating neuropsychiatric disorders. This marks a significant milestone with the enrollment of 30 subjects across five cohorts, receiving doses up to 1,000 micrograms.
纽约州纽约/ACCESSWIRE/2024年5月1日/生物制药创新的领导者Protagenic Therapeutics, Inc.（纳斯达克股票代码：PTIX）今天宣布，其1期试验的单剂量部分已完成注册，该试验涉及其合成压力调节肽 PT00114，用于治疗神经精神疾病。这标志着一个重要的里程碑，共招收了五个群组的30名受试者，接受的剂量高达1,000微克。
PT00114 has demonstrated outstanding tolerability with no adverse safety findings, building upon safety validations reported earlier this year. The trial progresses as PT00114 shows potential to transform treatment for anxiety, depression, PTSD, and addiction.
在今年早些时候报告的安全验证基础上，PT00114 表现出卓越的耐受性，没有不良的安全发现。随着 PT00114 显示出改变焦虑、抑郁、创伤后应激障碍和成瘾治疗方法的潜力，该试验正在取得进展。
"Completing this phase is an important step toward developing a safe, effective therapy for those affected by severe stress-related conditions," stated Dr. Maurizio Fava, Psychiatrist-in-Chief at Massachusetts General Hospital and Principal Investigator of the study.
麻省综合医院首席精神科医生、该研究的首席研究员毛里齐奥·法瓦博士说：“完成这一阶段是为受严重压力相关疾病影响的人开发安全、有效的治疗方法的重要一步。”
Data from this safety trial phase are anticipated to be announced in May. The study also includes assessments of biomarkers including cortisol levels before and after treatment.
该安全试验阶段的数据预计将于5月公布。该研究还包括对生物标志物的评估，包括治疗前后的皮质醇水平。
Protagenic Therapeutics continues to lead in the development of neuro-active peptides, addressing the profound need for innovative treatments in mental health.
Protagenic Therapeutics继续在神经活性肽的开发方面处于领先地位，满足了心理健康对创新疗法的迫切需求。
For more details, visit .
欲了解更多详情，请访问。
About PT00114:
PT00114 is a candidate to become a therapeutic for severe neuropsychiatric conditions, mimicking the naturally occurring brain peptide TCAP to counteract stress-induced hormonal effects.
关于 PT00114：
PT00114 模仿天然存在的大脑肽 TCAP 来抵消压力引起的荷尔蒙效应，是治疗严重神经精神疾病的候选药物。
Forward-Looking Statements:
Statements in this release about future expectations are "forward-looking" and subject to risks and uncertainties. Investors are cautioned against placing undue reliance on such statements.
前瞻性陈述：
本新闻稿中关于未来预期的陈述是 “前瞻性的”，受风险和不确定性的影响。提醒投资者不要过分依赖此类声明。
Company Contact:
Alexander K. Arrow, MD, CFA
, Chief Financial Officer
, Protagenic Therapeutics, Inc. 149 Fifth Ave, Suite 500, New York, NY 10010. Tel: 213-260-4342
Email: alex.arrow@protagenic.com
公司联系人：
亚历山大·阿罗，医学博士，特许金融分析师
，首席财务官
，Protagenic Therapeutics, Inc. 第五大道 149 号，套房 500，纽约，纽约州 10010。电话：213-260-4342
电子邮件：alex.arrow@protagenic.com
Investor Relations Contact:
Kirin M. Smith, President, PCG Advisory, Inc. 950 Third Avenue, Suite #2700, New York, NY 10022. Tel: 646-823-8656 Email: ksmith@pcgadvisory.com
投资者关系联系人：
Kirin M. Smith，PCG Advisory, Inc. 总裁。第三大道950号，套房 #2700，纽约，纽约州，10022。电话：646-823-8656 电子邮件：ksmith@pcgadvisory.com
SOURCE: Protagenic Therapeutics, Inc.
来源：Protagenic Therapeutics, Inc.
译文内容由第三方软件翻译。